Pro-Dex, Inc. (NASDAQ:PDEX) CFO Sells $40,020.00 in Stock

by · The Cerbat Gem

Pro-Dex, Inc. (NASDAQ:PDEX – Get Free Report) CFO Alisha Charlton sold 1,000 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $40.02, for a total value of $40,020.00. Following the completion of the sale, the chief financial officer now directly owns 15,339 shares of the company’s stock, valued at $613,866.78. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Pro-Dex Stock Up 5.0 %

PDEX traded up $2.04 during trading on Friday, reaching $43.14. 14,828 shares of the stock were exchanged, compared to its average volume of 13,698. The stock has a market cap of $140.64 million, a P/E ratio of 26.69 and a beta of 0.39. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.94 and a current ratio of 3.41. The stock’s 50 day moving average price is $28.86 and its two-hundred day moving average price is $22.55. Pro-Dex, Inc. has a twelve month low of $15.70 and a twelve month high of $46.50.

Pro-Dex (NASDAQ:PDEX – Get Free Report) last issued its earnings results on Thursday, September 5th. The medical instruments supplier reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.35 by $0.11. The company had revenue of $15.03 million for the quarter. Pro-Dex had a net margin of 9.17% and a return on equity of 16.74%. Equities analysts expect that Pro-Dex, Inc. will post 1.42 EPS for the current year.

Institutional Investors Weigh In On Pro-Dex

A number of large investors have recently added to or reduced their stakes in PDEX. Dimensional Fund Advisors LP boosted its position in Pro-Dex by 5.1% during the second quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock worth $1,238,000 after purchasing an additional 3,067 shares during the period. Bard Associates Inc. boosted its holdings in shares of Pro-Dex by 17.6% during the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after buying an additional 2,031 shares during the period. Renaissance Technologies LLC raised its holdings in Pro-Dex by 7.9% in the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock valued at $240,000 after acquiring an additional 900 shares during the period. Finally, Perritt Capital Management Inc. lifted its position in Pro-Dex by 43.3% during the first quarter. Perritt Capital Management Inc. now owns 6,000 shares of the medical instruments supplier’s stock worth $106,000 after acquiring an additional 1,813 shares during the last quarter. Institutional investors own 15.28% of the company’s stock.

Analyst Ratings Changes

PDEX has been the topic of several analyst reports. Ascendiant Capital Markets increased their target price on Pro-Dex from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, September 9th. StockNews.com raised shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 7th.

Check Out Our Latest Stock Report on Pro-Dex

Pro-Dex Company Profile

(Get Free Report)

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

Featured Stories